Adalimumab Expectations Revised In The Wake Of Amgen Launch

Analysts Outline Predictions And Weigh In On Key Questions Yet To Be Answered

Retaining market share in the face of competition
Analysts expect AbbVie to retain the vast majority of volume share in 2023 • Source: Shutterstock

More from Biosimilars

More from Products